Loading...
When added to other guideline-recommended therapies, the sodium-glucose cotransporter 2 inhibitor dapagliflozin has been shown to significantly reduce the risks for mortality and heart failure (HF) in patients with existing New York Heart Association classes II to IV HF and a left-ventricular ejection fraction ≤40%, regardless of type 2 diabetes status. On the heels of the industry-funded, randomized, placebo-controlled DAPA-HF trial (NCT03036124), which established that benefit (see NEJM JW Cardiol Nov 16 2019; [e-pub] and N Engl J Med 2019 Sep 19; [e-pub]), we have information from two additional analyses of the 4744 DAPA-HF participants.
Kosiborod and colleagues found that dapagliflozin's benefits were consistent across baseline levels of…